Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

Richard J Bold, Subbulakshi Virudachalam, David J. McConkey

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Background. Pancreatic cancer is extremely resistant to the induction of apoptosis by chemotherapies; agents that regulate sensitivity to apoptosis may lead to chemosensitization of pancreatic cancer. Materials and methods. MIA-PaCa-2 human pancreatic cancer cells were treated in vitro with the 26S-proteasome inhibitor PS-341. Levels of the apoptosis-regulating proteins (BCL-2, BAK, and BAX) were determined by Western blotting. The effect of PS-341 on BCL-2 gene transcription was examined using a BCL-2 promoter/luciferase reporter construct. The chemosensitizing effect of PS-341 was determined by measurement of the cytotoxic effect of gemcitabine in the presence of PS-341 (10-1000 nM) using the MTT assay. A corresponding in vivo experiment using tumor xenografts in athymic mice was also performed. Results. PS-341 decreased BCL-2, without effect on BAX or BAK. The downregulation of BCL-2 by PS-341 appears to be transcriptionally mediated. PS-341 induced apoptosis at high does (1000 nM) and increased the cytotoxicity of gemcitabine at low doses (10-100 nM). Xenograft growth was inhibited 59% by gemcitabine; the addition of PS-341 increased growth inhibition to 75%. Conclusions. Inhibition of the 26S proteasome disrupts the cellular content of key regulators of cell cycle progression and apoptotic control leading to increased sensitivity to standard chemotherapeutic agents, such as gemcitabine, in pancreatic cancer. Combination therapy may lead to better response rates.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalJournal of Surgical Research
Volume100
Issue number1
DOIs
StatePublished - 2001

Fingerprint

gemcitabine
Pancreatic Neoplasms
Apoptosis
Heterografts
Induction Chemotherapy
Proteasome Inhibitors
Bortezomib
ATP dependent 26S protease
Growth
Luciferases
Nude Mice
Cell Cycle
Down-Regulation
Western Blotting
Genes
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. / Bold, Richard J; Virudachalam, Subbulakshi; McConkey, David J.

In: Journal of Surgical Research, Vol. 100, No. 1, 2001, p. 11-17.

Research output: Contribution to journalArticle

Bold, Richard J ; Virudachalam, Subbulakshi ; McConkey, David J. / Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. In: Journal of Surgical Research. 2001 ; Vol. 100, No. 1. pp. 11-17.
@article{329f066236894a148214777297623dc9,
title = "Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome",
abstract = "Background. Pancreatic cancer is extremely resistant to the induction of apoptosis by chemotherapies; agents that regulate sensitivity to apoptosis may lead to chemosensitization of pancreatic cancer. Materials and methods. MIA-PaCa-2 human pancreatic cancer cells were treated in vitro with the 26S-proteasome inhibitor PS-341. Levels of the apoptosis-regulating proteins (BCL-2, BAK, and BAX) were determined by Western blotting. The effect of PS-341 on BCL-2 gene transcription was examined using a BCL-2 promoter/luciferase reporter construct. The chemosensitizing effect of PS-341 was determined by measurement of the cytotoxic effect of gemcitabine in the presence of PS-341 (10-1000 nM) using the MTT assay. A corresponding in vivo experiment using tumor xenografts in athymic mice was also performed. Results. PS-341 decreased BCL-2, without effect on BAX or BAK. The downregulation of BCL-2 by PS-341 appears to be transcriptionally mediated. PS-341 induced apoptosis at high does (1000 nM) and increased the cytotoxicity of gemcitabine at low doses (10-100 nM). Xenograft growth was inhibited 59{\%} by gemcitabine; the addition of PS-341 increased growth inhibition to 75{\%}. Conclusions. Inhibition of the 26S proteasome disrupts the cellular content of key regulators of cell cycle progression and apoptotic control leading to increased sensitivity to standard chemotherapeutic agents, such as gemcitabine, in pancreatic cancer. Combination therapy may lead to better response rates.",
author = "Bold, {Richard J} and Subbulakshi Virudachalam and McConkey, {David J.}",
year = "2001",
doi = "10.1006/jsre.2001.6194",
language = "English (US)",
volume = "100",
pages = "11--17",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

AU - Bold, Richard J

AU - Virudachalam, Subbulakshi

AU - McConkey, David J.

PY - 2001

Y1 - 2001

N2 - Background. Pancreatic cancer is extremely resistant to the induction of apoptosis by chemotherapies; agents that regulate sensitivity to apoptosis may lead to chemosensitization of pancreatic cancer. Materials and methods. MIA-PaCa-2 human pancreatic cancer cells were treated in vitro with the 26S-proteasome inhibitor PS-341. Levels of the apoptosis-regulating proteins (BCL-2, BAK, and BAX) were determined by Western blotting. The effect of PS-341 on BCL-2 gene transcription was examined using a BCL-2 promoter/luciferase reporter construct. The chemosensitizing effect of PS-341 was determined by measurement of the cytotoxic effect of gemcitabine in the presence of PS-341 (10-1000 nM) using the MTT assay. A corresponding in vivo experiment using tumor xenografts in athymic mice was also performed. Results. PS-341 decreased BCL-2, without effect on BAX or BAK. The downregulation of BCL-2 by PS-341 appears to be transcriptionally mediated. PS-341 induced apoptosis at high does (1000 nM) and increased the cytotoxicity of gemcitabine at low doses (10-100 nM). Xenograft growth was inhibited 59% by gemcitabine; the addition of PS-341 increased growth inhibition to 75%. Conclusions. Inhibition of the 26S proteasome disrupts the cellular content of key regulators of cell cycle progression and apoptotic control leading to increased sensitivity to standard chemotherapeutic agents, such as gemcitabine, in pancreatic cancer. Combination therapy may lead to better response rates.

AB - Background. Pancreatic cancer is extremely resistant to the induction of apoptosis by chemotherapies; agents that regulate sensitivity to apoptosis may lead to chemosensitization of pancreatic cancer. Materials and methods. MIA-PaCa-2 human pancreatic cancer cells were treated in vitro with the 26S-proteasome inhibitor PS-341. Levels of the apoptosis-regulating proteins (BCL-2, BAK, and BAX) were determined by Western blotting. The effect of PS-341 on BCL-2 gene transcription was examined using a BCL-2 promoter/luciferase reporter construct. The chemosensitizing effect of PS-341 was determined by measurement of the cytotoxic effect of gemcitabine in the presence of PS-341 (10-1000 nM) using the MTT assay. A corresponding in vivo experiment using tumor xenografts in athymic mice was also performed. Results. PS-341 decreased BCL-2, without effect on BAX or BAK. The downregulation of BCL-2 by PS-341 appears to be transcriptionally mediated. PS-341 induced apoptosis at high does (1000 nM) and increased the cytotoxicity of gemcitabine at low doses (10-100 nM). Xenograft growth was inhibited 59% by gemcitabine; the addition of PS-341 increased growth inhibition to 75%. Conclusions. Inhibition of the 26S proteasome disrupts the cellular content of key regulators of cell cycle progression and apoptotic control leading to increased sensitivity to standard chemotherapeutic agents, such as gemcitabine, in pancreatic cancer. Combination therapy may lead to better response rates.

UR - http://www.scopus.com/inward/record.url?scp=0034875305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034875305&partnerID=8YFLogxK

U2 - 10.1006/jsre.2001.6194

DO - 10.1006/jsre.2001.6194

M3 - Article

VL - 100

SP - 11

EP - 17

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -